10/26/2014 Weekend Routine - EP

Notable Earning in past week.

(1) RGLS
BioTech Play, normally beyond my understanding. The chart is beautiful and Volume/Price surge is huge. It has 11.3M float, EP day volume >20M

Hepatitis C is an insanely crowded and competitive field, but investors see in the early Regulus RG-101 data the potential for a new way to cure the liver disease with a single or even a few simple and easily tolerate, under-the-skin injections, instead of four, eight or 12 weeks of daily pills.

(2) IRBT
It is 20/100 kind of earning, may have 25%-50% potential. Float is 28M, target $45.

Revenue for the third quarter of 2014 was $143.5 million, compared with $124.5 million for the same quarter one year ago.
Net income in the third quarter of 2014 was $14.6 million, compared with $7.8 million in the third quarter of 2013.
Quarterly earnings per share were $0.48 for the third quarter of 2014, compared with $0.26 in the third quarter last year.